All In Biotech

Drug Trial Radar · NCT05513703

A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants With Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Phase 2, Open-Label Study in Subjects With Previously Untreated MET Amplified Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Last checked: Nov 20, 2026Latest source record: Oct 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

9

Actual

Start

Nov 21, 2022

Primary completion

Oct 28, 2024

Study completion Oct 28, 2024

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Aug 24, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study is to determine how telisotuzumab vedotin affects the disease state in adult participants with previously untreated participants with MET amplified non-squamous NSCLC. Change in disease activity will be assessed. Telisotuzumab vedotin is an investigational drug being developed for the treatment of MET amplified non-squamous NSCLC. Participants receive intravenously (IV) infused of telisotuzumab vedotin. Approximately 70 adult participants with previously untreated MET amplified locally advanced/metastatic non-squamous NSCLC will be enrolled in the study in approximately 110 sites worldwide. Participants will receive IV telisotuzumab vedotin every 2 weeks until meeting study drug discontinuation criteria. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Conditions

  • Non Small Cell Lung Cancer

Interventions

  • Telisotuzumab VedotinBiological

    Intravenous (IV) Infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR) as Assessed by an Independent Central Review (ICR)Time frame: Up to approximately 1.5 years

Locations

29 sites in 9 countries. Site status is shown where the registry gives one.

  • Cancer and Blood Speciality Clinic - Los Alamitos /ID# 251671

    Los Alamitos, California

  • Valley Medical Center /ID# 251880

    Renton, Washington

  • Monash Health - Monash Medical Centre /ID# 247679

    Clayton, Victoria, Australia

  • Centre Jean Perrin /ID# 246268

    Clermont-Ferrand, France

  • CHU Lille - Hôpital Albert Calmette /ID# 246263

    Lille, Hauts-de-France, France

  • Hospices Civils de Lyon (HCL) - Hopital Louis Pradel /ID# 246267

    Bron, Rhone, France

  • Asklepios Fachkliniken Muenchen-Gauting /ID# 248082

    Gauting, Germany

  • Rabin Medical Center /ID# 248631

    Petah Tikva, Israel

  • Meir Medical Center /ID# 243208

    Kfar Saba, Central District, Israel

  • Rambam Health Care Campus /ID# 246781

    Haifa, H_efa, Israel

  • Hadassah Medical Center-Hebrew University /ID# 243298

    Jerusalem, Jerusalem, Israel

  • The Chaim Sheba Medical Center /ID# 243207

    Ramat Gan, Tel Aviv, Israel

  • IRCCS Istituti Fisioterapici Ospitalieri-Istituto Nazionale Tumori Regina Elena /ID# 247585

    Rome, Italy

  • Duplicate_Fondazione IRCCS San Gerardo dei Tintori /ID# 247584

    Monza, Monza E Brianza, Italy

  • Istituto di Candiolo Fondazione del Piemonte per l'Oncologia IRCCS /ID# 248329

    Candiolo, Torino, Italy

  • National Cancer Center Hospital East /ID# 250317

    Kashiwa-shi, Chiba, Japan

  • Duplicate_National Hospital Organization Kyushu Cancer Center /ID# 250714

    Fukuoka, Fukuoka, Japan

  • Hokkaido University Hospital /ID# 250316

    Sapporo, Hokkaido, Japan

  • Osaka International Cancer Institute /ID# 251507

    Osaka, Osaka, Japan

  • Shizuoka Cancer Center /ID# 251752

    Sunto-gun, Shizuoka, Japan

  • National Cancer Center Hospital /ID# 250319

    Chuo-ku, Tokyo, Japan

  • Keimyung University Dongsan Hospital /ID# 247371

    Daegu, Gyeongsangbuk-do, South Korea

  • Pusan National University Yangsan Hospital /ID# 248489

    Yangsan, Gyeongsangnam-do, South Korea

  • Chungbuk National University Hospital /ID# 248405

    Cheongju-si, North Chungcheong, South Korea

  • Samsung Medical Center /ID# 248407

    Seoul, Seoul Teugbyeolsi, South Korea

  • Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 248144

    Kaohsiung City, Taiwan

  • National Cheng Kung University Hospital /ID# 248142

    Tainan, Taiwan

  • Linkou Chang Gung Memorial Hospital /ID# 248145

    Taoyuan City, Taiwan

  • Kaohsiung Chang Gung Memorial Hospital /ID# 248143

    Kaohsiung City, Kaohsiung, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.